Thyrocare Technologies Ltd Q2FY26 | When Wellness Met Wealth: 80% Profit Surge, 2:1 Bonus, ₹7 Dividend — and a Lab Empire That Works Overnight While Investors Sleep Soundly
The lab that never sleeps just dropped its Q2FY26 report card — and let’s just say the test results came back positive. Thyrocare Technologies, India’s OG of diagnostic efficiency, clocked revenue of ₹217 crore (+22% YoY) and PAT of ₹48 crore (+80% YoY). For a business built on testing blood samples, this quarter was pure adrenaline.
The company, now trading at ₹1,242 with a ₹6,591 crore market cap, declared a 2:1 bonus issue and ₹7/share interim dividend, because nothing says “healthy business” like giving your shareholders a free vitamin boost. It’s debt-light (₹24.7 crore total), ROE of 16.2%, and ROCE of 24.8% — metrics so clean even their labs couldn’t find a contaminant.
The stock trades at a cholesterol-level-high P/E of 51.6x, but when your profit jumps 80%, investors don’t complain — they just say “Aarogyam ho gaya.”
2. Introduction – From Hormones to Home ECGs
Once upon a time, Thyrocare was known for testing just thyroid levels. Today, it’s testing the patience of competitors. Founded on the simple idea that healthcare shouldn’t need a loan, the company became India’s go-to diagnostics chain by combining volume, automation, and a pinch of Dr. Velumani’s madness.
Fast-forward to FY26 — the company has evolved from a single-hormone hero to a full-blown diagnostics ecosystem. It now runs 929 tests and 288 profiles, processes 3 billion investigations annually, and can scale up to 10 billion (that’s one blood test for every Indian… thrice).
Its “Aarogyam” wellness packages are as common in Indian households as Maggi noodles, and its newer “Jaanch” and “Her Check” series aim to make health screening as routine as Netflix renewals. Meanwhile, acquisitions like Polo Labs (Punjab) and Vimta Labs’ diagnostics unit (Telangana & Andhra) expanded its geographical reach — because why stop at western India when you can be pan-India, pan-blood-type?
3. Business Model – WTF Do They Even Do?
Thyrocare is basically the Amazon of diagnostics — collect samples from everywhere, process them centrally, and deliver results faster than your local hospital can find the lab key.
Here’s the recipe:
1️ Franchise Model (63% of revenue): With 11,249 active franchisees, the company doesn’t open expensive branches — it partners with existing clinics, hospitals, and nursing homes. These franchisees collect samples and ship them overnight to Thyrocare’s central or regional labs — 4.6 lakh tests per night. Think of it as a medical version of Swiggy, but instead of food, it delivers reports.
2️ Partnerships & B2G (31%): The company partners with aggregators, corporate wellness programs, and government schemes. They do everything from school checkups to employee health audits.
3️ Direct to Consumer (6%): They’ll also come home and take your blood sample — no clinic drama. Their ECG-at-home service (acquired via Think Health) now covers 1,000+ pincodes, operated by 170 trained phlebotomists, aka “vampires with badges”.
Bonus Points:
All 29 labs are NABL-accredited — only 2% of Indian labs can claim that.
The network spans 2 central labs, 19 regional, 2 zonal, 6 satellites, plus a Tanzania JV. Because nothing says global like checking hemoglobin in Dar es Salaam.
4. Financials Overview
Metric
Latest Qtr (Q2FY26)
YoY Qtr (Q2FY25)
Prev Qtr (Q1FY26)
YoY %
QoQ %
Revenue
₹217 Cr
₹177 Cr
₹193 Cr
+22.1%
+12.4%
EBITDA
₹71 Cr
₹48 Cr
₹58 Cr
+47.9%
+22.4%
PAT
₹48 Cr
₹26 Cr
₹38 Cr
+79.9%
+26.3%
EPS (₹)
9.06
5.04
7.35
+80%
+23%
Commentary: Margins keep getting fitter — OPM jumped from 27% to 33%. The company’s cost control and operational leverage deserve a fitness influencer endorsement. It’s also now hitting revenue per test of ₹37, up from ₹35 — proving Indians are okay paying ₹2 extra for early cancer screening but not for parking.
5. Valuation Discussion – Fair Value Range Only
Method 1: P/E Based Approach
EPS (FY25): ₹24.1
Industry P/E (Healthcare Diagnostics): 40x–65x
Fair P/E Range: 45x–55x → Fair Value Range: ₹1,085 – ₹1,325 per share
Method 2: EV/EBITDA
EV = ₹6,545 Cr
EBITDA (FY25) = ₹228 Cr → EV/EBITDA = 28.7x Peer range (Dr Lal: ~26x, Vijaya: ~30x, Metropolis: ~32x) → Fair EV/EBITDA Range = 25x–30x → Price Range ₹1,150 – ₹1,300
